Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Hayleigh Collins - Director and Head of Corporate Communications Sean Nolan - CEO Sukumar Nagendran - President and Head of Research and Development Salman Bhai - Assistant Professor of Neurology at UT Kamran Alam - CFO Conference Call Participants Abigail Gray - Baird Gil Blum - Needham & Co. Operator Thank you for standing by. This is the conference operator. Welcome to the Taysha Gene T ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39536 Taysha Gene Therapies, Inc. (Exact Name of Registrant as Specified in its Charter) ( State or other jurisdiction of inco ...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2022 Earnings Conference Call March 28, 2023 4:30 PM ET Company Participants Hayleigh Collins - Director and Head of Corporate Communications Sean Nolan - Chief Executive Officer Sukumar Nagendran - President and Head of Research and Development Kamran Alam - Chief Financial Officer Conference Call Participants Whitney Ijem - Canaccord Genuity Jack Allen - Robert W. Baird & Co. Silvan Tuerkcan - JMP Securities Yun Zhong - BTIG David Hoang - SMBC Nikko Securities ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ WASHINGTON, DC 20549 FORM 10-K Commission File Number: 001-39536 Taysha Gene Therapies, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 84-31995 ...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2022 Results Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Kimberly Lee - Chief Corporate Affairs Officer RA Session - President, Founder and Chief Executive Officer Suyash Prasad - Chief Medical Officer and Head of Research and Development Kamran Alam - Chief Financial Officer Fred Porter - Chief Technical Officer Conference Call Participants Gil Blum - Needham & Company, LLC Geulah Livshits - Chardan Mehdi Goudarzi - Truist Securitie ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39536 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ (Exact Name of Registrant as Specified in its Charter) Delaware 84-3199512 ( State or other jur ...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q2 2022 Results Conference Call August 11, 2022 8:00 AM ET Company Participants Dr. Kimberly Lee - Chief Corporate Affairs Officer RA Session - President, Founder, and Chief Executive Officer Dr. Suyash Prasad - Chief Medical Officer and Head, R&D Kamran Alam - Chief Financial Officer Dr. Frederick Porter - Chief Technical Officer Conference Call Participants Joon Lee - Jo Securities Gil Blum - Needham & Company Mike Ulz - Morgan Stanley Eun Yang - Jefferies Jack Al ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39536 Taysha Gene Therapies, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 84-31995 ...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2022 Earnings Conference Call May 16, 2022 8:00 AM ET Company Participants Kimberly Lee - Chief Corporate Affairs Officer RA Session II - President, Founder, and Chief Executive Officer Suyash Prasad - Chief Medical Officer and Head, R&D Kamran Alam - Chief Financial Officer Conference Call Participants Gil Blum - Needham & Company Elizabeth Webster - Goldman Sachs Kevin DeGeeter - Oppenheimer & Company Jack Allen - Baird Yun Zhong - BTIG Laura Chico - Wedbush Se ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39536 Taysha Gene Therapies, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 84-3199 ...